Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Monterey, California • Orange, California + 14 more

Conditions: Scar, Hypertrophic Scar, Mammary Disorder
Interventions: Botulinum Toxins, Normal saline; Drug · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Ibuprofen, placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atrial Fibrillation, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Surgical Recovery, Pain, Postoperative
Interventions: N-acetyl cysteine, Normal Saline; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Clostridium Difficile Infection (CDI)
Interventions: RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence); Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 60
States / cities: Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions: Angiotensin 1-7, Saline solution; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 45 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Phoenix, Arizona • Tucson, Arizona

Conditions: Moderate-to-severely Painful Ankle Surgery
Interventions: Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: CRPS, Chronic Regional Pain Syndrome
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 17 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Ventricular Arrythmia
Interventions: Half-normal saline, Normal saline; Drug
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Austin, Texas

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Leandro, California + 28 more

Conditions: Healthy
Interventions: Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline; Drug · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 36 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions: C1 Esterase Inhibitor, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: CMS, Placebo; Drug · Other
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Newport Beach, California • Palm Springs, California • Reseda, California + 22 more

Conditions: Induction of Labor Affected Fetus / Newborn
Interventions: Lactated ringers, 5% dextrose lactated ringers; Other
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Surgical Site Infection
Interventions: Povidone-Iodine, Normal Saline; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Kansas City, Missouri • Philadelphia, Pennsylvania

Conditions: Salt Sensitivity of Blood Pressure
Interventions: Hypertonic Saline with furosemide, Hypertonic Saline without furosemide; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Seizures
Interventions: Bumetanide, Normal Saline as Placebo; Drug
Lead sponsor: Soul, Janet , M.D.; Individual
Eligibility: Up to 44 Weeks
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Pain, Postoperative, Ankle Fractures
Interventions: Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Reperfusion Injury
Interventions: Ascorbic Acid, 5 % Dextrose Water or Normal Saline; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hernia
Interventions: Normal saline, Midazolam; Other · Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel; Biological · Other · Drug
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more

Search by objective public record fields.

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Oxidative Stress and Surgical Recovery

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Biomarker Study: Heart Failure Patients at Risk

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation

Study of LJP 394 in Lupus Patients With History of Renal Disease

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

The Use of D5LR Versus LR for Induction of Labor and Time to Delivery in Multiparous and Primiparous Patient's With Favorable and Unfavorable Bishop's Scores

Bacterial Contamination: Iodine vs Saline Irrigation in Pediatric Spine Surgery

Central Sodium Sensing: Implications for Blood Pressure Regulation

Pilot Study of Bumetanide for Newborn Seizures

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC